- seekingalpha.com
- Posted On 14 November 2026
Savara: The Market May Be Overestimating Its FDA Risk
Eljaye W. Tellis is a medicinal chemistry Ph.D. candidate and biotech investor. He covers biotechnology and healthcare equities, applying a therapeutic discover...
Source:
seekingalpha.com